<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2014-1-ENG-27-31</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-587</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>“КОНТРАСТ” ИССЛЕДОВАНИЕ: СРАВНЕНИЕ НЕФРОПРОТЕКТИВНОСТИ ТРЕХ ПРОТОКОЛОВ: АЦЕТИЛЦИСТЕИН — НАТРИЯ БИКАРБОНАТ — ТЕОФИЛЛИН, ДЛЯ ПРЕДОТВРАЩЕНИЯ КОНТРАСТ- ИНДУЦИРОВАННОЙ НЕФРОПАТИИ</article-title><trans-title-group xml:lang="en"><trans-title>“CONTRAST” STUDY: COMPARİSİON OF NEPHROPROTECTİVE THREE PROTOCOLS: ACETYLCYSTEİNESODİUM BİCARBONATE-THEOPHYLLİNE, TO PREVENT CONTRAST-İNDUCED NEPHROPATHY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Caglar</surname><given-names>Ilker Murat</given-names></name><name name-style="western" xml:lang="en"><surname>Caglar</surname><given-names>Ilker Murat</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Turhan Caglar</surname><given-names>Fatma Nihan</given-names></name><name name-style="western" xml:lang="en"><surname>Turhan Caglar</surname><given-names>Fatma Nihan</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Conkbayir</surname><given-names>Cenk</given-names></name><name name-style="western" xml:lang="en"><surname>Conkbayir</surname><given-names>Cenk</given-names></name></name-alternatives><bio xml:lang="en"><p>Assist Prof Dr, Altan Kamil Str No 15 Ortakoy, Nicosia (north), Cyprus, Tel: +90 533 877 50 42</p></bio><email xlink:type="simple">cenkconk@hotmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Baskurt</surname><given-names>Murat</given-names></name><name name-style="western" xml:lang="en"><surname>Baskurt</surname><given-names>Murat</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Akturk</surname><given-names>Faruk</given-names></name><name name-style="western" xml:lang="en"><surname>Akturk</surname><given-names>Faruk</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Dasli</surname><given-names>Tolga</given-names></name><name name-style="western" xml:lang="en"><surname>Dasli</surname><given-names>Tolga</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Okcun</surname><given-names>Baris</given-names></name><name name-style="western" xml:lang="en"><surname>Okcun</surname><given-names>Baris</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-7"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="en">Dr.Sadi konuk bakirkoy education and research hospital, cardiology department, Bakırkoy, Istanbul, Turkey</aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="en">Istanbul Education and research hospital, cardiology department, Fatih, Istanbul, Turkey</aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="en">3Near East university, cardiology department,&#13;
Nicosia (North), Cyprus</aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="en">Medicana hospital, cardiology department, Bahcelievler, Istanbul, Turkey</aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="en">Mehmet akif ersoy education and research hospital, cardiology department, Halkali, Istanbul, Turkey</aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="en">Eyup state hospital, cardiology department, Eyup, Istanbul, Turkey</aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="en">Istanbul university cardiology institute, cardiology department, Fatih, Istanbul, Turkey</aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>28</day><month>01</month><year>2014</year></pub-date><volume>0</volume><issue>1-ENG</issue><fpage>27</fpage><lpage>31</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Caglar I.M., Turhan Caglar F.N., Conkbayir C., Baskurt M., Akturk F., Dasli T., Okcun B., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Caglar I.M., Turhan Caglar F.N., Conkbayir C., Baskurt M., Akturk F., Dasli T., Okcun B.</copyright-holder><copyright-holder xml:lang="en">Caglar I.M., Turhan Caglar F.N., Conkbayir C., Baskurt M., Akturk F., Dasli T., Okcun B.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/587">https://russjcardiol.elpub.ru/jour/article/view/587</self-uri><abstract><sec><title>Цель</title><p>Цель. Целью данного исследования стало сравнение трех профилактических режимов терапии: гидратации на основе натрия бикарбоната, натрия бикарбоната + N-ацетилцистеин (NAC), натрия бикарбоната + NAC + теофиллин, для профилактики контраст-индуцированной нефропатии.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Мы рандомизировали 151 больного с исходной скоростью клубочковой фильтрации (СКФ) со значениями между 30–59 мл/ мин/1.73м 2, которые проходили коронарную ангиографию, с тремя профилактическими схемами лечения: внутривенная гидратация натрия бикарбонатом (3 мл/кг/час в течение 1 часа до и через 1 мл/кг/ч в течение 6 часов после контрастного воздействия, 1 группа; n=50), гидратация + NAC (600 мг перорально, два раза в день, предшествующий день и день ангиографии, 2 группа; n=50), и гидратация + NAC + теофиллин (600 мг перорально NAC и 200 мг теофиллина перорально дважды в день в течение предыдущего дня и в день ангиографии, 3-я группа; n=51). Появление контраст-индуцированной нефропатии (0,5 мг/дл увеличение сывороточного креатинина от базового уровня через 48 часов после внутрисосудистого введения контраста) сравнивали в трех группах.</p></sec><sec><title>Результаты</title><p>Результаты. Из 151 пациентов, у 4 больных (на 7,8%) в группе 3 была отмечена контраст-индуцированная нефропатия (p=0.01). Контраст-индуцированная нефропатия не развивалась в группах 1 и 2.</p></sec><sec><title>Заключение</title><p>Заключение. Среди пациентов со значениями СКФ между 30–59 мл/мин/1.73м 2 при прохождении коронарной ангиографии, использование гидратации только натрия бикарбонатом и натрия бикарбонатом с NAC было связано со снижением частоты контраст-индуцированной нефропатии. Терапия натрия бикарбонатом с теофиллином не оказалась действенной в профилактике контраст-индуцированной нефропатии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. The purpose of this study was to compare three prophylactic regimens, sodium-bicarbonate based hydration, sodium-bicarbonate + N-acetylcysteine (NAC), and sodium-bicarbonate + NAC + theophylline, for the prevention of contrast induced nephropathy.</p></sec><sec><title>Material and methods</title><p>Material and methods. We prospectively randomized 151 patients with baseline eGFR values between 30–59 ml/min/1.73m² who were also undergoing coronary angiography with three prophylactic treatments: intravenous hydration with sodiumbicarbonate (3 ml/kg/h for 1 hours before and 1 ml/kg/h for 6 hours after contrast exposure, group 1; n=50), hydration + NAC (600 mg p. o. twice daily the preceding day and the day of angiography, group 2; n=50), and hydration + NAC + theophylline (600 mg p. o. NAC and 200 mg theophylline p. o. twice daily for the preceding day and the day of angiography, group 3; n=51). The incidence of contrast induced nephropathy (0,5 mg/dl increase in serum creatinine from the baseline value 48 hours after intravascular injection of contrast) from the three groups was compared.</p></sec><sec><title>Results</title><p>Results. Of the 151 patients, 4 patients (7.8%) in group 3 experienced CIN (p=0.01). CIN did not develop in group 1 and 2.</p></sec><sec><title>Conclusion</title><p>Conclusion. Among patients with eGFR values between 30–59 ml/min/1.73m² undergoing coronary angiography, use of sodium-bicarbonate based hydration alone and sodium-bicarbonate with NAC was associated with a reduction in the rate of contrast induced nephropathy. Sodium-bicarbonate with theophylline therapy was found to have no effect for the prevention of contrast-induced nephropathy.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>контраст нефропатия</kwd><kwd>ангиография</kwd></kwd-group><kwd-group xml:lang="en"><kwd>contrast nephropathy</kwd><kwd>angiography</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Charles H, Hennekens C. Increasing burden of cardiovascular disease. Current knowledge and future directions for research on risk factors. Circulation. 1998;97:1095–102.</mixed-citation><mixed-citation xml:lang="en">Charles H, Hennekens C. Increasing burden of cardiovascular disease. Current knowledge and future directions for research on risk factors. Circulation. 1998;97:1095–102.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–42.</mixed-citation><mixed-citation xml:lang="en">Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–42.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Laskey W, Boyle J, Johson LW. Multivariate model for prediction of risk of significant complication during diagnostic cardiac catheteri zation. Cathet Cardiovasc Diagn 1993;30:185–90.</mixed-citation><mixed-citation xml:lang="en">Laskey W, Boyle J, Johson LW. Multivariate model for prediction of risk of significant complication during diagnostic cardiac catheteri zation. Cathet Cardiovasc Diagn 1993;30:185–90.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Donald SB, Daniel IS.Complications and the optimal use of adjunctive pharmacology. In: Donald SB, eds. Grossman’s cardiac catheterization, angiography, and intervention. 7th ed. Philadelphia: Lippincott Williams and Williams; 2007; 36–75.</mixed-citation><mixed-citation xml:lang="en">Donald SB, Daniel IS.Complications and the optimal use of adjunctive pharmacology. In: Donald SB, eds. Grossman’s cardiac catheterization, angiography, and intervention. 7th ed. Philadelphia: Lippincott Williams and Williams; 2007; 36–75.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kern MJ, Roth R. Introduction to the catheterization laboratory. In: Kern MJ, ed. The cardiac catheterization handbook. 4th ed. Philadelphia: Mosby;2003; 1–51.</mixed-citation><mixed-citation xml:lang="en">Kern MJ, Roth R. Introduction to the catheterization laboratory. In: Kern MJ, ed. The cardiac catheterization handbook. 4th ed. Philadelphia: Mosby;2003; 1–51.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin. 2005;21:261–80.</mixed-citation><mixed-citation xml:lang="en">McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin. 2005;21:261–80.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tumlin J, Stacul F, Adam A, et al. CIN Consensus Working Panel. Pathophysiology of contrastinduced nephropathy. Am J Cardiol. 2006;98: 14K-20K.</mixed-citation><mixed-citation xml:lang="en">Tumlin J, Stacul F, Adam A, et al. CIN Consensus Working Panel. Pathophysiology of contrastinduced nephropathy. Am J Cardiol. 2006;98: 14K-20K.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">McCullough PA, Adam A, Becker CR, et al. CIN Consensus Working Panel. Epidemiology and Prognostic Implications of Contrast-Induced Nephropathy.Am J Cardiol. 2006;98: 5K-13K.</mixed-citation><mixed-citation xml:lang="en">McCullough PA, Adam A, Becker CR, et al. CIN Consensus Working Panel. Epidemiology and Prognostic Implications of Contrast-Induced Nephropathy.Am J Cardiol. 2006;98: 5K-13K.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Meschi M, Detrenis S, Musini S, Strada E, Savazzi G. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med. 2006;34: 2060–8.</mixed-citation><mixed-citation xml:lang="en">Meschi M, Detrenis S, Musini S, Strada E, Savazzi G. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med. 2006;34: 2060–8.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiographyrelated renal tissue injury (the APART trial). Am J Cardiol. 2002;89: 356–8.</mixed-citation><mixed-citation xml:lang="en">Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiographyrelated renal tissue injury (the APART trial). Am J Cardiol. 2002;89: 356–8.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Scholze A, Rinder C, Beige J, et al.Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with endstage renal failure. Circulation. 2004 Jan 27;109: 369–74.</mixed-citation><mixed-citation xml:lang="en">Scholze A, Rinder C, Beige J, et al.Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with endstage renal failure. Circulation. 2004 Jan 27;109: 369–74.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant. 2004;19: 2747–53.</mixed-citation><mixed-citation xml:lang="en">McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant. 2004;19: 2747–53.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol. 2003;9: 1157–62.</mixed-citation><mixed-citation xml:lang="en">Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol. 2003;9: 1157–62.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Stacul F, Adam A, Becker CR, et al. CIN Consensus Working Panel. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol.2006;9;18: 59–77.</mixed-citation><mixed-citation xml:lang="en">Stacul F, Adam A, Becker CR, et al. CIN Consensus Working Panel. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol.2006;9;18: 59–77.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Venkataraman R. Prevention of acute renal failure. Crit Care Clin. 2005;21:281–9.</mixed-citation><mixed-citation xml:lang="en">Venkataraman R. Prevention of acute renal failure. Crit Care Clin. 2005;21:281–9.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Baskurt M, Okcun B, Abaci O, et al. N-acetylcysteine versus N-acetylcysteine+theophylline for the prevention of contrast nephropathy. Eur J Clin Invest. 2009;39 (9): 793–9.</mixed-citation><mixed-citation xml:lang="en">Baskurt M, Okcun B, Abaci O, et al. N-acetylcysteine versus N-acetylcysteine+theophylline for the prevention of contrast nephropathy. Eur J Clin Invest. 2009;39 (9): 793–9.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ozcan E, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007 September; 539–44.</mixed-citation><mixed-citation xml:lang="en">Ozcan E, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007 September; 539–44.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hogan S, L’Allier P, Chetcuti S, et al. Current role of sodim bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: A meta-analysis. Am Heart J. 2008; vol156;3: 414–21.</mixed-citation><mixed-citation xml:lang="en">Hogan S, L’Allier P, Chetcuti S, et al. Current role of sodim bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: A meta-analysis. Am Heart J. 2008; vol156;3: 414–21.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Maioli M, Toso A, Leoncini M, et al. Sodium Bicarbonate Versus Saline for the Prevention of Contrast-Induced Nephropathy in patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention. J Am Coll Car. 2008; vol52;8:599–604.</mixed-citation><mixed-citation xml:lang="en">Maioli M, Toso A, Leoncini M, et al. Sodium Bicarbonate Versus Saline for the Prevention of Contrast-Induced Nephropathy in patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention. J Am Coll Car. 2008; vol52;8:599–604.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Mayoral A, Chaparro M, Prado B, et al. The Reno-Protective Effect of Hydration With Sodium Bicarbonate Plus N-Acetylcysteine in Patients Undergoing Emergency Percutaneous Coronary Intervention (The RENO Study). J Am Coll Car. 2007; vol 49;12:1283–88.</mixed-citation><mixed-citation xml:lang="en">Mayoral A, Chaparro M, Prado B, et al. The Reno-Protective Effect of Hydration With Sodium Bicarbonate Plus N-Acetylcysteine in Patients Undergoing Emergency Percutaneous Coronary Intervention (The RENO Study). J Am Coll Car. 2007; vol 49;12:1283–88.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lameire N, Adam A, Becker CR, et al. CIN Consensus Working Panel. Baseline renal function screening. Am J Cardiol. 2006;98: 21K-26K.</mixed-citation><mixed-citation xml:lang="en">Lameire N, Adam A, Becker CR, et al. CIN Consensus Working Panel. Baseline renal function screening. Am J Cardiol. 2006;98: 21K-26K.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ix JH, McCullogh CE, Chertow GM. Theophylline fort he prevention of radiocontrasr nephropathy: a meta analysis. Nephrol Dial Transplant. 2004;19: 2747–53.</mixed-citation><mixed-citation xml:lang="en">Ix JH, McCullogh CE, Chertow GM. Theophylline fort he prevention of radiocontrasr nephropathy: a meta analysis. Nephrol Dial Transplant. 2004;19: 2747–53.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Demir M, Kutlucan A, Akın H, et al. Comparision of different agents on radiographic contrast agent induced nephropathy. Eur J Gen Med 2008;5 (4):222–7.</mixed-citation><mixed-citation xml:lang="en">Demir M, Kutlucan A, Akın H, et al. Comparision of different agents on radiographic contrast agent induced nephropathy. Eur J Gen Med 2008;5 (4):222–7.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bagshaw SM, Ghali WA. Theophylline for Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis. Arch Intern Med. 2005;165:1087–93.</mixed-citation><mixed-citation xml:lang="en">Bagshaw SM, Ghali WA. Theophylline for Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis. Arch Intern Med. 2005;165:1087–93.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast induced acute renal failure after coronary angioplaty in patients with preexisting renal insufficiency. Am J Cardiol 1999;83:260–3.</mixed-citation><mixed-citation xml:lang="en">Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast induced acute renal failure after coronary angioplaty in patients with preexisting renal insufficiency. Am J Cardiol 1999;83:260–3.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Malhis M, Al-Bitar S, Al-Deen K. The role of throphylline inprevention of radiocontrast mediainduced nephropathy. Saudi J Kidney Dis Transpl 2010;21 (2):276–83.</mixed-citation><mixed-citation xml:lang="en">Malhis M, Al-Bitar S, Al-Deen K. The role of throphylline inprevention of radiocontrast mediainduced nephropathy. Saudi J Kidney Dis Transpl 2010;21 (2):276–83.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">http://www.drugs.com/drug-interactions/theophylline.html</mixed-citation><mixed-citation xml:lang="en">http://www.drugs.com/drug-interactions/theophylline.html</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
